Of the 100+ biotech finance and accounting leaders we surveyed, more than 40% cite clinical trial accruals as their biggest headache. 94% see site budget overruns. 75% select CROs based on capabilities, not price or timeline. These and other insights comprise our latest research, The Clinical Trial Financial Management Playbook.
The Playbook covers a wide range of topics across biotech finance and accounting, including how biotechs have navigated the rollercoaster year of 2022, maximizing the success of your contracting and procurement efforts, bringing data and insight to bear across your forecasting and accruals workflows, optimizing your technology for success, and much more. This is one bit of reading you won't want to miss.